PT  - JOURNAL ARTICLE
AU  - Skitchenko, Rostislav
AU  - Modrusan, Zora
AU  - Loboda, Alexander
AU  - Kopp, Jeffrey B.
AU  - Winkler, Cheryl A.
AU  - Sergushichev, Alexey
AU  - Gupta, Namrata
AU  - Stevens, Christine
AU  - Daly, Mark J.
AU  - Shaw, Andrey
AU  - Artomov, Mykyta
TI  - <em>CR1</em> variants contribute to FSGS susceptibility across multiple populations
AID  - 10.1101/2023.11.20.23298462
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.11.20.23298462
4099  - http://medrxiv.org/content/early/2023/11/20/2023.11.20.23298462.short
4100  - http://medrxiv.org/content/early/2023/11/20/2023.11.20.23298462.full
AB  - Focal segmental glomerulosclerosis (FSGS) is a common cause of nephrotic syndrome with an annual incidence in the United States in African-Americans compared to European-Americans of 24 cases and 5 cases per million, respectively. Among glomerular diseases in Europe and Latin-America, FSGS was the second most frequent diagnosis, and in Asia the fifth. We expand previous efforts in understanding genetics of FSGS by performing a case-control study involving ethnically-diverse groups FSGS cases (726) and a pool of controls (13,994), using panel sequencing of approximately 2,500 podocyte-expressed genes. Through rare variant association tests, we replicated known risk genes – KANK1, COL4A4, and APOL1. A novel significant association was observed for the gene encoding complement receptor 1 (CR1). High-risk rare variants in CR1 in the European-American cohort were commonly observed in Latin-and African-Americans. Therefore, a combined rare and common variant analysis was used to replicate the CR1 association in non-European populations. The CR1 risk variant, rs17047661, gives rise to the Sl1/Sl2 (R1601G) allele that was previously associated with protection against cerebral malaria. Pleiotropic effects of rs17047661 may explain the difference in allele frequencies across continental ancestries and suggest a possible role for genetically-driven alterations of adaptive immunity in the pathogenesis of FSGS.Competing Interest StatementM.J.D. is a founder of Maze Therapeutics; A.S. and Z.M. are employees of Genentech Inc. Other authors have no competing interests to disclose.Funding StatementThis work was supported in part by the Intramural Research Program, NIDDK, NIH (JBK). This project has been funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract 75N91019D00024. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This Research was supported [in part] by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research and NIDDK. The authors acknowledge the contributions of the following investigators who recruited subjects for FSGS genetic studies, published in Kopp et al, Nature Genetics, 2008, as DNA from those subjects was used in the present study. These investigators include Kopp JB, Freedman BI, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H. R.S., Al.S. were supported by the Ministry of Science and Higher Education of the Russian Federation (Priority 2030 Federal Academic Leadership Program). A.L. was supported by Ministry of Science and Higher Education of the Russian Federation (Agreement # 075-15-2022-301). M.A. was in part supported by Nationwide Foundation Pediatric Innovation Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As all samples were de-identified, the Washington University in St. Louis Institutional Review Board (IRB) deemed that these studies did not require IRB approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes